HK1201466A1 - 用於治療糖尿病的β-內醯胺化合物 - Google Patents
用於治療糖尿病的β-內醯胺化合物Info
- Publication number
- HK1201466A1 HK1201466A1 HK15102059.7A HK15102059A HK1201466A1 HK 1201466 A1 HK1201466 A1 HK 1201466A1 HK 15102059 A HK15102059 A HK 15102059A HK 1201466 A1 HK1201466 A1 HK 1201466A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating diabetes
- lactam compounds
- beta lactam
- beta
- compounds
- Prior art date
Links
- -1 Beta lactam compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161537105P | 2011-09-21 | 2011-09-21 | |
PCT/IL2012/050378 WO2013042121A1 (en) | 2011-09-21 | 2012-09-20 | Beta-lactam compounds for treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201466A1 true HK1201466A1 (zh) | 2015-09-04 |
Family
ID=47913973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102059.7A HK1201466A1 (zh) | 2011-09-21 | 2015-03-02 | 用於治療糖尿病的β-內醯胺化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9474744B2 (zh) |
EP (1) | EP2758054B1 (zh) |
CN (1) | CN104023721A (zh) |
AU (1) | AU2012311050A1 (zh) |
BR (1) | BR112014005864A2 (zh) |
CA (1) | CA2850558A1 (zh) |
HK (1) | HK1201466A1 (zh) |
WO (1) | WO2013042121A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020210983B2 (en) * | 2019-01-23 | 2024-05-16 | Glycolysis Biomed Co., Ltd | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA94128B (en) | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
EP0869943A1 (en) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
US6255467B1 (en) | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
LV12403B (lv) | 1998-06-10 | 2000-02-20 | Latvijas Organiskās Sintēzes Institūts | Citotoksiskie penicilānskābes atvasinājumi |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
NZ517663A (en) | 1999-08-16 | 2006-02-24 | Revaax Pharmaceuticals Llc | Neurotherapeutic clavulanate composition and method |
US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
AU2003202942A1 (en) | 2002-01-17 | 2003-09-02 | R.E.D. Laboratories, N.V./S.A. | Methods of treatment of chronic immune disease |
US7026472B2 (en) | 2002-05-06 | 2006-04-11 | University Of South Florida | Methods for preventing and treating cancer using N-thiolated β-lactam compounds and analogs thereof |
WO2005121148A2 (en) | 2004-06-08 | 2005-12-22 | Nereus Pharmaceuticals, Inc. | Anti-bacterial and anti-cancer spiro beta-lactone/gamma-lactams |
ATE490976T1 (de) | 2004-10-30 | 2010-12-15 | Univ Pais Vasco | B-lactam-rgd-cyclopeptide mit gamma-(g-)wendungen |
AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
KR100697312B1 (ko) | 2005-08-31 | 2007-03-20 | 한국생명공학연구원 | 세프트리악손을 포함하는 stat3 활성 저해 활성을가지는 조성물 |
US8722343B2 (en) * | 2008-11-21 | 2014-05-13 | Carla Perego | Methods and compositions for the diagnosis and treatment of diabetes |
CN101524517A (zh) | 2009-04-28 | 2009-09-09 | 李红彬 | 一种治疗上呼吸道感染的中西复合药物 |
WO2011047153A1 (en) * | 2009-10-15 | 2011-04-21 | President And Fellows Of Harvard College | Methods for modulating autoimmunity |
WO2012103456A2 (en) | 2011-01-27 | 2012-08-02 | Board Of Regents, The University Of Texas System | Polycyclic beta lactam derivatives for the treatment of cancer |
-
2012
- 2012-09-20 CN CN201280046027.3A patent/CN104023721A/zh active Pending
- 2012-09-20 AU AU2012311050A patent/AU2012311050A1/en not_active Abandoned
- 2012-09-20 US US14/346,219 patent/US9474744B2/en not_active Expired - Fee Related
- 2012-09-20 BR BR112014005864A patent/BR112014005864A2/pt not_active IP Right Cessation
- 2012-09-20 CA CA2850558A patent/CA2850558A1/en not_active Abandoned
- 2012-09-20 EP EP12833374.7A patent/EP2758054B1/en not_active Not-in-force
- 2012-09-20 WO PCT/IL2012/050378 patent/WO2013042121A1/en active Application Filing
-
2015
- 2015-03-02 HK HK15102059.7A patent/HK1201466A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014005864A2 (pt) | 2017-03-28 |
CA2850558A1 (en) | 2013-03-28 |
CN104023721A (zh) | 2014-09-03 |
US20140234282A1 (en) | 2014-08-21 |
EP2758054A1 (en) | 2014-07-30 |
EP2758054B1 (en) | 2017-04-12 |
US9474744B2 (en) | 2016-10-25 |
EP2758054A4 (en) | 2015-03-04 |
WO2013042121A1 (en) | 2013-03-28 |
AU2012311050A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286152A (en) | Modified imidazopyridinyl-aminopyridine compounds | |
HK1202059A1 (zh) | 用於治療脊髓性肌萎縮症的化合物 | |
ZA201502811B (en) | Apparatus for motion compensation | |
HK1200484A1 (zh) | 多聚寡核苷酸化合物 | |
EP2902020A4 (en) | COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS | |
IL220889A (en) | Anti-dll4 antibody to treat diabetes | |
EP2709609A4 (en) | HETEROCYCLIC COMPOUNDS | |
IL230594A0 (en) | Process for the preparation of nitrogen-substituted 1h-pyrazole-5-carbonyl chloride compounds | |
IL253421B (en) | Compounds for the treatment of fibrosis (Leifat) | |
EP2590643A4 (en) | MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES | |
SG11201405296QA (en) | Method for purifying acetonitrile | |
EP2774917A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | |
HK1210969A1 (zh) | 用於疾病治療的取代的雜環化合物 | |
SG11201501216XA (en) | Method for purifying acetonitrile | |
PL3202769T3 (pl) | Sposoby oczyszczania związków fosfaplatyny | |
HK1201466A1 (zh) | 用於治療糖尿病的β-內醯胺化合物 | |
HK1190706A1 (zh) | 作為用於治療糖尿病的 抑制劑的仲-羥基環己基衍生物 | |
GB201117172D0 (en) | Diabetes | |
GB201105659D0 (en) | Compounds | |
EP2691104A4 (en) | USE OF EZATIOSTAT IN THE TREATMENT OF MULTIPLE MYELOMA | |
EP2683746A4 (en) | OLIGOSACCHARIDE COMPOUNDS | |
PL2578759T3 (pl) | Mechanizm ryglujący dla odpływu | |
EP2563353A4 (en) | COMPOUNDS FOR ANTIFUNGAL TREATMENT | |
HK1214960A1 (zh) | 用於純化肝素- -硫酸的方法 | |
IL231480A0 (en) | Beta-lactam compounds for the treatment of diabetes |